Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic…

Hematologic MalignanciesRare diseaseCancerDrugPhase 2

What this study is

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).

What's being tested

Nemtabrutinib
Intervention · DRUG
Nemtabrutinib tablets administered orally QD.

Study details

Official title: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies
Sponsor: Merck Sharp & Dohme LLC
Conditions: Hematologic Malignancies · Waldenstroms Macroglobulinaemia · Non-Hodgkins Lymphoma · Chronic Lymphocytic Leukaemia
Enrolling: 490 people
Starts: 2021-04-05
Est. completion: 2029-01-04
Design: Open-label, single group, Phase 2
Record: View on ClinicalTrials.gov ↗

Who can join

Age 18 Years and overSex ALLHealthy volunteers Not accepted

You may qualify if

Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 within 7 days before C1D1 (the first dose of study treatment)
Has a life expectancy of at least 3 months, based on the investigator assessment
Has the ability to swallow and retain oral medication
Participants who are Hepatitis B surface antigen (HBsAg)-positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization
Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening
Has adequate organ function
Male participants agree to refrain from donating sperm and agree to either remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle OR agree to use contraception, during the intervention period and for at least the time required to eliminate the study intervention after last dose of study intervention
Female participants assigned female sex at birth who are not pregnant or breastfeeding are eligible to participate if not a participant of childbearing potential (POCBP), or if a POCBP they either use a contraceptive method that is highly effective OR remain abstinent from penile-vaginal intercourse as their preferred and usual lifestyle during the intervention period and for at least to eliminate study intervention after the last dose of study intervention
Participants with Human immunodeficiency virus (HIV) are eligible if they meet all of the following: the CD4 count is >350 cells/uL at screening, the HIV viral load is below the detectable level, are on a stable ART regimen for at least 4 weeks prior to study entry, and are compliant with their ART Part 1 and Part 2 (Cohorts A to C and J)
Has a confirmed diagnosis of Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) with; At least 2 lines of prior therapy (Part 1 only); Part 2 Cohort A: CLL/SLL participants who are relapsed or refractory to prior therapy with a covalent, irreversible Bruton's tyrosine kinase inhibitor (BTKi), and a B-cell lymphoma 2 inhibitor (BCL2i). CLL participants must have received and failed, been intolerant to, or determined by their treating physician to be a poor phosphoinositide 3-kinase inhibitor (PI3Ki) candidate or ineligible for a PI3Ki per local guidelines; Part 2 Cohort B: CLL/SLL participants who are relapsed or refractory following at least 1 line of prior therapy and are BTKi treatment naive; Part 2 Cohort C: CLL/SLL participants with 17p deletion or tumor protein p53 (TP53) mutation who are relapsed or refractory following at least 1 line of prior therapy; Part 2 Cohort J: CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi and BCL2i. NOTE: As of Protocol Amendment 09, at least 10 CLL/SLL participants whose disease relapsed or was refractory to prior therapy with a covalent/irreversible BTKi, BCL2i and noncovalent/reversible BTKi (all three classes of therapies are required) will be enrolled into Cohort J; Has active disease for CLL/SLL clearly documented to initiate therapy; For SLL participants in Part 2: Has evaluable core or excisional lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate at Screening (optional for participants enrolling in Part 1) Part 2 (Cohorts D to G)
Has a confirmed diagnosis of and meets the following prior therapy requirements:; Participants with Richter's transformation who are relapsed or refractory following at least 1 line of prior therapy (Cohort D); Participants with pathologically confirmed Mantle-cell lymphoma (MCL), documented by either overexpression of cyclin D1 or t (11;14), who are relapsed or are refractory to chemoimmunotherapy and a covalent irreversible BTKi (Cohort E); Participants with Marginal zone lymphoma (MZL) (including splenic, nodal, and extra nodal MZL) who are relapsed or refractory to at least one prior line of systemic therapy including an anti-CD20-based regimen; Participants with Follicular lymphoma (FL) who are relapsed or refractory to chemoimmunotherapy and immunomodulatory agents (such as lenalidomide based regimen) (Cohort G); Have measurable disease defined as at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral Computed tomography (CT) scan; Has a lymph node biopsy for biomarker analysis from an archival or newly obtained biopsy or bone marrow aspirate (Cohort D) at Screening Part 2 (Cohort H): confirmed diagnosis of Waldenström's macroglobulinemia (WM); participants who are relapsed or refractory to standard therapies for WM including chemoimmunotherapy and a covalent irreversible BTKi; Has active disease defined as 1 of the following: systemic symptoms, physical findings, laboratory abnormalities, coexisting disease; Has measurable disease, satisfying any of the following: at least 1 lesion that can be accurately measured in at least 2 dimensions with spiral CT scan (minimum measurement must be >15 mm in the longest diameter or >10 mm in the short axis); IgM ≥450 mg/dL; or bone marrow infiltration of 10%; Has fresh bone marrow aspirate or a lymph node biopsy for biomarker analysis at Screening or a lymph node biopsy from an archival

You can't join if

Has active HBV/HCV infection (Part 1 and Part 2)
Has a history of malignancy ≤3 years before providing documented informed consent. Participants with basal cell carcinoma of skin, squamous cell carcinoma of skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potential curative therapy are not excluded. Participants with low-risk, early-stage prostate cancer (T1-T2a, Gleason score ≤6, and prostate-specific antigen <10 ng/mL) either treated with definitive intent or untreated in active surveillance with SD are not excluded
Has active central nervous system (CNS) disease
Has an active infection requiring systemic therapy
Has received prior systemic anti-cancer therapy within 5 half-lives or 4 weeks (if prior therapy was a monoclonal antibody) before C1D1
Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention
Has any clinically significant gastrointestinal abnormalities that might alter absorption
History of severe bleeding disorders

Study locations (121)

94 open

Highlands Oncology Group ( Site 2728)
Springdale, Arkansas, United States
- Study Coordinator · Contact479-872-8130
Recruiting
University of California San Diego Moores Cancer Center ( Site 2717)
La Jolla, California, United States
- Study Coordinator · Contact858-534-5201
Recruiting
Colorado Blood Cancer Institute ( Site 2726)
Denver, Colorado, United States
- Study Coordinator · Contact720-754-4800
Recruiting
Astera Cancer Care ( Site 2732)
East Brunswick, New Jersey, United States
- Study Coordinator · Contact732-672-6405
Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
Hackensack, New Jersey, United States
- Study Coordinator · Contact551-996-3003
Recruiting
UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
Dallas, Texas, United States
- Study Coordinator · Contact972-695-9450
Recruiting
Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
Spokane, Washington, United States
- Study Coordinator · Contact509-462-2273
Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
Torrance, California, United States
Completed
The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
Louisville, Kentucky, United States
Completed
Mayo Clinic - Rochester ( Site 2706)
Rochester, Minnesota, United States
Active, not recruiting
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
Fargo, North Dakota, United States
Completed

110 sites outside the US

Hospital Aleman ( Site 0102)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
- Study Coordinator · Contact+541148277000
Recruiting
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
Buenos Aires, Buenos Aires F.D., Argentina
- Study Coordinator · Contact+541152990247
Recruiting
Fundacion Estudios Clinicos ( Site 0112)
Rosario, Santa Fe Province, Argentina
- Study Coordinator · Contact+54 0341 238 4171
Recruiting
FUNDALEU ( Site 0104)
Caba, Argentina
- Study Coordinator · Contact5411 48771046
Recruiting
Hospital Privado Universitario de Córdoba ( Site 0107)
Córdoba, Argentina
- Study Coordinator · Contact+541569634187
Recruiting
Box Hill Hospital ( Site 0203)
Box Hill, Victoria, Australia
- Study Coordinator · Contact+611300342255
Recruiting
Sir Charles Gairdner Hospital ( Site 0200)
Nedlands, Western Australia, Australia
- Study Coordinator · Contact+61864573333
Recruiting
Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
São Paulo, São Paulo, Brazil
- Study Coordinator · Contact551145737543
Recruiting
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
Rio de Janeiro, Brazil
- Study Coordinator · Contact+552132076564
Recruiting
Hospital Paulistano - Amil Clinical Research ( Site 0311)
São Paulo, Brazil
- Study Coordinator · Contact+551130161340
Recruiting
Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
Calgary, Alberta, Canada
- Study Coordinator · Contact4035213723
Recruiting
The Ottawa Hospital ( Site 0404)
Ottawa, Ontario, Canada
- Study Coordinator · Contact613 737-7700
Recruiting
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
Toronto, Ontario, Canada
- Study Coordinator · Contact416-946-2827
Recruiting
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
Montreal, Quebec, Canada
- Study Coordinator · Contact5142523400
Recruiting
Jewish General Hospital ( Site 0400)
Montreal, Quebec, Canada
- Study Coordinator · Contact5143408222 x 24572
Recruiting
Peking University Third Hospital-Hematology ( Site 2827)
Beijing, Beijing Municipality, China
- Study Coordinator · Contact010-82266699
Recruiting
Liuzhou People's Hospital ( Site 2817)
Liuzhou, Guangxi, China
- Study Coordinator · Contact+8607722662950
Recruiting
Guangxi Medical University Cancer Hospital ( Site 2814)
Nanning, Guangxi, China
- Study Coordinator · Contact+8607715323174
Recruiting
Henan Cancer Hospital-hematology department ( Site 2802)
Zhengzhou, Henan, China
- Study Coordinator · Contact0371-65588007
Recruiting
Wuhan Union Hospital ( Site 2816)
Wuhan, Hubei, China
- Study Coordinator · Contact+8618627091655
Recruiting
The Second Xiangya Hospital of Central South University ( Site 2820)
Changsha, Hunan, China
- Study Coordinator · Contact+8613975806137
Recruiting
Hunan Cancer Hospital ( Site 2822)
Changsha, Hunan, China
- Study Coordinator · Contact0731-88651669
Recruiting
Jiangsu Province Hospital ( Site 2823)
Nanjing, Jiangsu, China
- Study Coordinator · Contact025-86211033
Recruiting
The First Affiliated Hospital of Nanchang University ( Site 2815)
Nanchang, Jiangxi, China
- Study Coordinator · Contact13970038386
Recruiting
The First Hospital of Jilin University-Hematology ( Site 2803)
Changchun, Jilin, China
- Study Coordinator · Contact0431-88786014
Recruiting
Fudan University Shanghai Cancer Center ( Site 2801)
Shanghai, Shanghai Municipality, China
- Study Coordinator · Contact+8602164175590
Recruiting
Huashan Hospital, Fudan University ( Site 2821)
Shanghai, Shanghai Municipality, China
- Study Coordinator · Contact021-52889999
Recruiting
West China Hospital Sichuan University ( Site 2810)
Chengdu, Sichuan, China
- Study Coordinator · Contact+86028-85422114
Recruiting
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio ( Site 2800)
Tianjin, Tianjin Municipality, China
- Study Coordinator · Contact+8615900265415
Recruiting
The First Affiliated Hospital, Zhejiang University ( Site 2826)
Hangzhou, Zhejiang, China
- Study Coordinator · Contact057187236114
Recruiting
Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0600)
Brno, Brno-mesto, Czechia
- Study Coordinator · Contact+420532233642
Recruiting
Fakultni nemocnice Hradec Kralove ( Site 0601)
Hradec Králové, Czechia
- Study Coordinator · Contact+420495832159
Recruiting
Aalborg Universitetshospital ( Site 0703)
Aalborg, North Denmark, Denmark
- Study Coordinator · Contact+45 97660000
Recruiting
Sjællands Universitetshospital Køge ( Site 0701)
Koege, Region Sjælland, Denmark
- Study Coordinator · Contact+45 46323200
Recruiting
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0810)
Nice, Alpes-Maritimes, France
- Study Coordinator · Contact+33 4 92 03 57 85
Recruiting
Centre Hospitalier Lyon-Sud ( Site 0804)
Pierre-Bénite, Auvergne-Rhône-Alpes, France
- Study Coordinator · Contact+33478864348
Recruiting
Institut Paoli-Calmettes ( Site 0803)
Marseille, Bouches-du-Rhone, France
- Study Coordinator · Contact+33491223537
Recruiting
Hopital Saint Louis ( Site 0805)
Paris, France
- Study Coordinator · Contact+33142499236
Recruiting
Universitaetsklinikum Ulm. ( Site 0906)
Ulm, Baden-Wurttemberg, Germany
- Study Coordinator · Contact+ 49 731 500 45901
Recruiting
Universitaetsklinikum Koeln ( Site 0901)
Cologne, North Rhine-Westphalia, Germany
- Study Coordinator · Contact+4922147897046
Recruiting
Universitaetsklinikum Carl Gustav Carus ( Site 0902)
Dresden, Saxony, Germany
- Study Coordinator · Contact0049 351 458 5692
Recruiting
Pecsi Tudomanyegyetem Altalanos Orvostudomanyi Kar ( Site 1202)
Pécs, Baranya, Hungary
- Study Coordinator · Contact+3672536000
Recruiting
Debreceni Egyetem Klinikai Kozpont ( Site 1201)
Debrecen, Hajdú-Bihar, Hungary
- Study Coordinator · Contact+3652255196
Recruiting
Szabolcs Szatmár Bereg Vármegyei Oktatókórház ( Site 1206)
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary
- Study Coordinator · Contact+3642599700
Recruiting
Orszagos Onkologiai Intezet ( Site 1200)
Budapest, Hungary
- Study Coordinator · Contact+3612248600
Recruiting
Beaumont Hospital ( Site 2900)
Dublin, Ireland
- Study Coordinator · Contact+35318092010
Recruiting
Ha Emek Medical Center ( Site 1305)
Afula, Israel
- Study Coordinator · Contact972-46494052
Recruiting
Soroka Medical Center ( Site 1307)
Beersheba, Israel
- Study Coordinator · Contact+97286403827
Recruiting
Rambam Medical Center ( Site 1301)
Haifa, Israel
- Study Coordinator · Contact+97247772547
Recruiting
Hadassah Ein Karem Jerusalem ( Site 1300)
Jerusalem, Israel
- Study Coordinator · Contact+97226778180
Recruiting
Chaim Sheba Medical Center ( Site 1302)
Ramat Gan, Israel
- Study Coordinator · Contact+97235308401
Recruiting
Kaplan Medical Center ( Site 1304)
Rehovot, Israel
- Study Coordinator · Contact+97289441726
Recruiting
Sourasky Medical Center ( Site 1303)
Tel Aviv, Israel
- Study Coordinator · Contact+97236973782
Recruiting
A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1400)
Bologna, Italy
- Study Coordinator · Contact+390516363680
Recruiting
ASST Spedali Civili di Brescia ( Site 1408)
Brescia, Italy
- Study Coordinator · Contact+39 0303996416
Recruiting
IRCCS Ospedale San Raffaele ( Site 1402)
Milan, Italy
- Study Coordinator · Contact00390226434797
Recruiting
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1403)
Naples, Italy
- Study Coordinator · Contact+39 0815903 382
Recruiting
Fondazione IRCCS Policlinico San Matteo ( Site 1407)
Pavia, Italy
- Study Coordinator · Contact+39 0382503084
Recruiting
IRCCS - Arcispedale Santa Maria Nuova ( Site 1405)
Reggio Emilia, Italy
- Study Coordinator · Contact+39 0522295654
Recruiting
Pratia MCM Krakow ( Site 1601)
Krakow, Lesser Poland Voivodeship, Poland
- Study Coordinator · Contact48 12 2954135
Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site 1608)
Warsaw, Masovian Voivodeship, Poland
- Study Coordinator · Contact+48225462223
Recruiting
Spitalul Clinic Colțea ( Site 1805)
Bucharest, Bucharest, Romania
- Study Coordinator · Contact0040213874100
Recruiting
Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 1802)
Brasov, Romania
- Study Coordinator · Contact0729075567
Recruiting
Institutul Regional de Oncologie Iasi ( Site 1801)
Iași, Romania
- Study Coordinator · Contact40374278811
Recruiting
Severance Hospital Yonsei University Health System ( Site 2201)
Seoul, South Korea
- Study Coordinator · Contact+82222281972
Recruiting
Samsung Medical Center ( Site 2200)
Seoul, South Korea
- Study Coordinator · Contact+82234106548
Recruiting
Instituto Catalan de Oncologia ICO - Hospital Duran i Reynals ( Site 2000)
L'Hospitalet de Llobregat, Barcelona, Spain
- Study Coordinator · Contact+34932607750
Recruiting
Hospital Universitario de Salamanca ( Site 2002)
Salamanca, Castille and León, Spain
- Study Coordinator · Contact34923 29 11 00x55974
Recruiting
CHUAC-Complejo Hospitalario Universitario A Coruña ( Site 2005)
A Coruña, La Coruna, Spain
- Study Coordinator · Contact34981178000
Recruiting
Hospital General Universitario de Alicante ( Site 2007)
Alicante, Spain
- Study Coordinator · Contact965 93 30 00
Recruiting
Hospital Universitari Vall d'Hebron ( Site 2001)
Barcelona, Spain
- Study Coordinator · Contact+34934893806
Recruiting
Hospital Universitario 12 de Octubre ( Site 2003)
Madrid, Spain
- Study Coordinator · Contact+34917792809
Recruiting
Hospital Puerta de Hierro ( Site 2009)
Madrid, Spain
- Study Coordinator · Contact+34911916000
Recruiting
Inselspital Bern ( Site 2303)
Bern, Canton of Bern, Switzerland
- Study Coordinator · Contact+41316329023
Recruiting
Istituto Oncologica della Svizzera Italiana (IOSI) ( Site 2302)
Bellinzona, Canton Ticino, Switzerland
- Study Coordinator · Contact+41918118540
Recruiting
Ankara Universitesi Tip Fakultesi Cebeci Hastanesi ( Site 2400)
Ankara, Turkey (Türkiye)
- Study Coordinator · Contact+903125957099
Recruiting
Sisli Florence Nightingale Hastanesi ( Site 2407)
Istanbul, Turkey (Türkiye)
- Study Coordinator · Contact+90 542 502 50 75
Recruiting
Instit. of Blood Transfusion Medicine of the National Academy ( Site 2506)
Lviv, Lviv Oblast, Ukraine
- Study Coordinator · Contact+380322352276
Recruiting
National Cancer Institute ( Site 2507)
Kyiv, Ukraine
- Study Coordinator · Contact+380672091427
Recruiting
Bristol Haematology and Oncology Centre ( Site 2610)
Bristol, Bristol, City of, United Kingdom
- Study Coordinator · Contact01173426733
Recruiting
Nottingham University Hospitals NHS Trust. City Hospital Campus ( Site 2601)
Nottingham, England, United Kingdom
- Study Coordinator · Contact+441159691169
Recruiting
GenesisCare - Windsor ( Site 2608)
Windsor, England, United Kingdom
- Study Coordinator · Contact+447989474250
Recruiting
Sarah Cannon Research Institute UK ( Site 2612)
London, London, City of, United Kingdom
- Study Coordinator · Contact02032195234
Recruiting
GenesisCare - Oxford ( Site 2607)
Oxford, Oxfordshire, United Kingdom
- Study Coordinator · Contact+447989474250
Recruiting
GenesisCare - Cambridge ( Site 2611)
Newmarket, Suffolk, United Kingdom
- Study Coordinator · Contact01223 655145
Recruiting
The Royal Marsden NHS Foundation Trust. ( Site 2606)
Sutton, Surrey, United Kingdom
- Study Coordinator · Contact020 8642 6011
Recruiting
The Christie NHS Foundation Trust ( Site 2602)
Manchester, United Kingdom
- Study Coordinator · Contact01619561217
Recruiting
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
Mendoza, Argentina
Completed
Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
Sydney, New South Wales, Australia
Completed
BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
São Paulo, Brazil
Active, not recruiting
Anhui Provincial Hospital ( Site 2808)
Hefei, Anhui, China
Active, not recruiting
The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
Chongqing, Chongqing Municipality, China
Active, not recruiting
Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
Guangzhou, Guangdong, China
Active, not recruiting
The Affiliated Hospital of Xuzhou Medical College ( Site 2818)
Xuzhou, Jiangsu, China
Completed
Aarhus University Hospital ( Site 0702)
Aarhus N, Central Jutland, Denmark
Completed
Odense University Hospital ( Site 0705)
Odense C, Region Syddanmark, Denmark
Completed
Centre Hospitalier de Versailles ( Site 0809)
Le Chesnay, Yvelines, France
Completed
St. Marien-Krankenhaus Siegen ( Site 0914)
Siegen, North Rhine-Westphalia, Germany
Completed
University Hospital Limerick ( Site 2903)
Limerick, Ireland
Active, not recruiting
Istituto Tumori Giovanni Paolo II ( Site 1409)
Bari, Italy
Completed
Policlinico Umberto I ( Site 1404)
Roma, Italy
Completed
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1606)
Wroclaw, Lower Silesian Voivodeship, Poland
Completed
Szpital Wojewódzki w Opolu-Hematology Department ( Site 1607)
Opole, Opole Voivodeship, Poland
Completed
Szpitale Pomorskie Sp. z o.o. ( Site 1600)
Gdynia, Pomeranian Voivodeship, Poland
Completed
Ovidius Clinical Hospital ( Site 1804)
Ovidiu, Constanța County, Romania
Completed
Mega Medipol-Hematology ( Site 2406)
Stanbul, Istanbul, Turkey (Türkiye)
Active, not recruiting
VKV Amerikan Hastanesi ( Site 2403)
Istanbul, Turkey (Türkiye)
Completed
Dokuz Eylül Üniversitesi-Hematology ( Site 2402)
Izmir, Turkey (Türkiye)
Active, not recruiting
MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2509)
Cherkassy, Cherkasy Oblast, Ukraine
Active, not recruiting
Communal non-profit enterprise "Regional clinical hospital o-Hematology Department ( Site 2510)
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Completed

Nemtabrutinib for blood cancers including leukemia and lymphoma

What this study is

What's being tested

Study details

Who can join

Monitoring & Endpoints

Study locations (121)

Study team

Merck Sharp & Dohme LLC

Medical Director

Toll Free Number

Frequently asked questions